Advertisement
  1. Home
  2. Pharmaceutical
  3. global-rett-syndrome-treatment-market
Image

Global Rett Syndrome Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Rett Syndrome Market, By Types (Classic Rett Syndrome, Atypical Rett Syndrome), Stages (Stage IV Late Motor Deterioration, Stage III Plateau, Stage II Rapid Destruction, Stage I Early Onset), Drug Type (Branded, Generics), Route Of Administration (Oral, Parenteral, Others), Diagnosis (Blood Test, Genetic Testing, Others), Treatment (Medication, Physical Therapy, Occupational Therapy, Speech language Therapy, Others), Dosage Form (Tablets, Capsules, Liquid, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Rett Syndrome Market

Market Analysis and Size                              

Rett syndrome is an uncommon neurological condition that affects mostly girls. Developmental difficulties, loss of motor abilities, and speech are all symptoms of the condition. Furthermore, the syndrome is diagnosed in children aged 6 to 18 months and is caused by mutations in the MECP2 gene on the X-chromosome. Rett syndrome can cause various problems, ranging from moderate to severe. Unusual eye movements, delayed growth, agitation and anger, poor language abilities, hand movement problems, muscular and coordination challenges, and breathing problems are all common symptoms of Rett syndrome.

Data Bridge Market Research analyses that the Rett syndrome market was valued at USD 783.11 thousand in 2021 and is expected to reach USD 70,797.27 thousand by 2029, registering a CAGR of 75.6% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Thousand, Volumes in Units, Pricing in USD

Segments Covered

Types (Classic Rett Syndrome, Atypical Rett Syndrome), Stages (Stage IV Late Motor Deterioration, Stage III Plateau, Stage II Rapid Destruction, Stage I Early Onset), Drug Type (Branded, Generics), Route Of Administration (Oral, Parenteral, Others), Diagnosis (Blood Test, Genetic Testing, Others), Treatment (Medication, Physical Therapy, Occupational Therapy, Speech language Therapy, Others), Dosage Form (Tablets, Capsules, Liquid, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), WOCKHARDT (Mumbai), Novo Nordisk A/S (Denmark), Glenmark Pharmaceuticals Limited (India), Cipla Inc. (U.S.), Bausch Health Companies Inc. (Canada), Otsuka America Pharmaceutical, Inc. (U.S.), Johnson & Johnson Private Limited (U.S.), Takeda Pharmaceutical Company Limited (Japan), Sumitomo Corporation (Japan), Biocon (India)

Market Opportunities

  • Rising number of research and development activities

  • New product launches

Market Definition

Rett syndrome is rare neurological condition that primarily affects women. It is caused by a random gene mutation. Almost all patients require caregiver assistance throughout their lives. Many children with Rett syndrome reach adulthood with a high quality of life. Because there is no cure for Rett syndrome, treatment focuses on symptom management. The majority of afflicted children will benefit from occupational, physical, and speech treatment. Seizures, anxiety, sleep disorders, breathing problems, stereotypic hand movements, and certain gastrointestinal abnormalities are all signs of Rett syndrome that can be treated with drugs. Drugs can also help with muscular stiffness and spasticity.

Rett Syndrome Market Dynamics

Drivers

  • Increasing prevalence of Rett syndrome

The increasing prevalence of Rett syndrome will fuel industry growth. The mutation in the MECP2 gene causes Rett syndrome. On the long arm of chromosome X, the MECP2 gene encodes the methyl- CpG binding protein 2. Symptoms appear as people grow older. Infants with Rett syndrome grow normally for the first six months before showing symptoms of the disease. The frequent alterations usually appear between the ages of 12 and 18 months.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Rett syndrome market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, a rise in the number of government initiatives to spread awareness and a rising level of disposable income will enhance the market's growth rate. The increasing number of female population across the globe along with the high spending on public health programs for females are expected to enhance the market's growth rate.

Opportunities

  • New product launches

The surging number of product launches is estimated to create new opportunities for the growth rate of Rett syndrome market. For instance, the US Food and Medication Administration designated AMO-04, a glutamate modulator for the treatment of Rett syndrome, as an orphan drug in June 2018. This recognition is a significant step forward in the development of this syndrome, highlighting the urgent need for a new therapeutic option for Rett syndrome.

  • Increase in the number of research and development activities    

The Rett syndrome market's growth is fueled by the rise in the number of research and development activities. This will further create new market opportunities during the forecast period of 2022-2029.

Moreover, the market's growth is fueled by the development of gene therapy for Rett Syndrome and emerging new markets. These factors will provide beneficial opportunities for the Rett syndrome market growth.

Restraints/Challenges

  • Complications involved with Rett syndrome

Complications associated with this disease is anticipated to hinder the market's growth rate. Some Rett syndrome symptoms can raise a child's chance of developing health problems. Aspiration pneumonia, for instance, can be caused by swallowing or breathing problems. When food, saliva, or other liquids enter the lungs instead of the stomach, this type of pneumonia develops. Scoliosis patients are more likely to suffer lung difficulties. Uncontrolled seizures can also put you at risk for health problems.

On the other hand, the high cost of symptomatic treatment, therapies, and diagnostic methods will obstruct the market's growth rate. The shortage of healthcare infrastructure in developing economies and shortage of skilled professionals will challenge the Rett syndrome market. Additionally, lack of awareness and strict government regulations will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Rett syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Rett syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Females are almost entirely affected by Rett syndrome. Rett syndrome affects about one in every 10,000 to 15,000 infant females. It affects children of all races and ethnicity.

Rett syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Acquisition

  • In December 2021, Acadia Pharmaceuticals Inc. announced the positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years suffering from Rett syndrome. Trofinetide is an experimental medication. It's a new synthetic analogue of IGF-1's aminoterminal tripeptide that could help with Rett syndrome's fundamental symptoms by lowering neuroinflammation and supporting synaptic function. Trofinetide is expected to promote synaptic maturation and help patients overcome the synaptic and neuronal immaturities that are common in Rett syndrome.

Global Rett Syndrome Market Scope

The Rett syndrome market is segmented on the basis of types, stages, treatment, drug type, dosage form, route of administration, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

  • Classic Rett Syndrome

  • Atypical Rett Syndrome

Stages

  • Stage IV Late Motor Deterioration

  • Stage III Plateau

  • Stage II Rapid Destruction

  • Stage I Early Onset

Drug Type

  • Branded

  • Generics

Route Of Administration

  • Oral

  • Parenteral

  • Others

Diagnosis

  • Blood Test

  • Genetic Testing

  • Others

Treatment

  • Medication

  • Anticonvulsants

  • Others 

  • Physical Therapy

  • Occupational Therapy

  • Speech language Therapy

  • Others

Dosage Form

  • Tablets

  • Capsules

  • Liquid

  • Others

End-Users

  • Hospitals

  • Specialty Clinics

  • Homecare

  • Others

Distribution Channel

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

  • Others

Rett syndrome market Regional Analysis/Insights

The Rett syndrome market is analysed and market size insights and trends are provided by country, types, stages, treatment, drug type, dosage form, route of administration, end-user and distribution channel as referenced above.

The countries covered in the Rett syndrome market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Rett syndrome market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of FDA approved wound debridement devices and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, favorable health remuneration policies, rise in chronic wounds, and a growing elderly population will further propel the market's growth rate in this region.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to increase in the number of insurance payers in this region. Also, the development of private healthcare sector and rising awareness among the people will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Rett Syndrome Market Share Analysis

The Rett syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Rett syndrome market.

Some of the major players operating in the Rett syndrome market are:

  • Merck KGaA (Germany)

  • Eisai Co., Ltd. (Japan)

  • AstraZeneca (U.K.)

  • Sanofi (France)

  • Novartis AG (Switzerland)

  • Abbott (U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Teva Pharmaceutical Industries Ltd. (Ireland)

  • Pfizer Inc. (U.S.)

  • GlaxoSmithKline plc (U.K.)

  • WOCKHARDT (Mumbai)

  • Novo Nordisk A/S (Denmark)

  • Glenmark Pharmaceuticals Limited (India)

  • Cipla Inc. (U.S.)

  • Bausch Health Companies Inc. (Canada)

  • Otsuka America Pharmaceutical, Inc. (U.S.)

  • Johnson & Johnson Private Limited (U.S.)

  • Takeda Pharmaceutical Company Limited (Japan)

  • Sumitomo Corporation (Japan)

  • Biocon (India) 

SKU-
Advance Formative Research Customization
Request for bulk
Reports
Why Choose Us
Flowers


Frequently Asked Questions

The market value for Rett syndrome market is expected USD 70,797.27 thousand by 2029.
The Rett syndrome market is to grow at a CAGR of 75.6% during the forecast period of 2022 to 2029
The global Rett syndrome market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market.
The major companies providing the global Rett syndrome are Zydus Cadila, Viatris Inc., Hikma Pharmaceuticals PLC, LUPIN, Teva Pharmaceutical USA (a subsidiary of Teva Pharmaceutical Industries Ltd.), Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Cipla Inc., Glenmark Pharmaceuticals Inc. USA (A Subsidiary of Glenmark Pharmaceuticals Ltd.), Anavex Life Sciences Corp, AMO PHARMA, Novartis AG, UCB SA, Sun Pharmaceutical Industries Ltd., Pfizer Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.), Otsuka Pharmaceuticals Co., Ltd (a subsidiary of Otsuka Holdings Co., Ltd), Aspen Holdings, Validus Pharmaceuticals LLC, H. LUNDBECK A/S, Aurobindo Pharma USA (A Subsidiary of Aurobindo Pharma), and Children’s Hospital Colorado among others.

Browse Related Blogs

Global Rett Syndrome Market is Growing with 75.1% CAGR in the Forecast Period of 2021 to 2028


Browse Related Press Release

GlaxoSmithKline plc. Janssen Pharmaceuticals, Inc. (a subsidiary of Johnson & Johnson Services, Inc.) and H. Lundbeck A/S are Dominating the Global Rett Syndrome Market in 2021


Advertisement

REPORTS

MARKET INSIGHT

SUPPORT

SOLUTIONS

DMCA Protected © DataBridge - All Rights Reserved.